Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15903995 | 0.89 | PDE10A (0.59) | PDE10AKMT2AIMPDH2ADORA3ADORA2A | |
| SCHEMBL15904309 | 0.83 | PDE10A (0.61) | PDE10AKMT2A | |
| SCHEMBL15903784 | 0.76 | PDE10A (0.53) | PDE10AKMT2A | |
| SCHEMBL15905356 | 0.74 | PDE10A (0.84) | PDE10A | |
| SCHEMBL15903997 | 0.74 | KDM4E (0.49) | PDE10AKMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL15402620 | 0.71 | MKNK2 (0.43) | PDE10AMKNK2 | |
| SCHEMBL15904846 | 0.69 | PDE10A (1.00) | PDE10A | |
| SCHEMBL2557652 | 0.69 | KMT2A (0.53) | KMT2AADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL15904208 | 0.69 | PDE10A (0.50) | PDE10AKMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL881833 | 0.68 | MKNK2 (0.50) | PDE10AKMT2AMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | disclosed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | disclosed |
| EP-2948443-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-12-02 | — | — | EP | disclosed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | disclosed |
| WO-2014114695-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L (ES) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PDE12, PDE5A, PDE10A | PDE10A 3/4885KMT2A 2522/4885MKNK2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.